Peltan argues validation, not discovery, limits drug timelines, citing retatrutide's path from 2019 trials to a planned 2027 filing as counterfeit versions already circulate.
Recap by typeshit. Post by Egan Peltan on X.
Tara Wider has spent about five years posting on holistic beauty and women's wellness, building a following of women her age on social media.
Brown says diet and exercise still matter, but argues that shaming people for treating obesity with medication has never made anyone healthier.
A short share on growing GLP-1 use in the US, with no figures or sources attached. Thin on detail beyond the headline itself.
A new survey covered by Chain Store Age tracks how GLP-1 users are shifting their food spending from restaurants toward grocery stores.
Lilly's triple agonist outperformed semaglutide on both weight and blood sugar in people with type 2 diabetes, per Medscape's report on the head-to-head data.
On his podcast, the NHS GP cites studies suggesting hunger hormones rebound within weeks and that people regain about 60% of lost weight within a year.
Loading…